

<https://helda.helsinki.fi>

An Expert Opinion From the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects

Benetos, Athanase

2016-05

Benetos , A , Bulpitt , C J , Petrovic , M , Ungar , A , Rosei , E A , Cherubini , A , Redon , J , Grodzicki , T , Dominiczak , A , Strandberg , T & Mancia , G 2016 , ' An Expert Opinion From the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects ' , Hypertension , vol. 67 , no. 5 , pp. 820-825 . <https://doi.org/10.1161/HYPERTENSIONAHA.115.07020>

<http://hdl.handle.net/10138/163047>

<https://doi.org/10.1161/HYPERTENSIONAHA.115.07020>

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

An Expert Opinion From the European Society of Hypertension–European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects

Athanase Benetos,* Christopher J. Bulpitt,* Mirko Petrovic, Andrea Ungar, Enrico Agabiti Rosei, Antonio Cherubini, Josep Redon, Tomasz Grodzicki, Anna Dominiczak, Timo Strandberg, Giuseppe Mancina

Two years after the publication of the 2013 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC),¹ the ESH and the European Union Geriatric Medicine Society have created a common working group to examine the management of hypertensive subjects aged >80 years. The general term hypertension in the elderly is not sufficiently accurate because it mixes younger old patients (60–70 years) with the oldest old. Our group believes that the management of hypertension in individuals aged ≥80 years should be specifically addressed. Although arbitrary, this cutoff value identifies a population that is expanding faster than any other age group with a 50% increase of life expectancy during the past 50 years^{2,3}; furthermore, the incidence and prevalence of comorbidities, frailty, and loss of autonomy greatly increases after the age of 80 years⁴; finally, although there is limited evidence on the management of hypertension in this age group, the latest clinical studies indicate that in these patients, treatment may not be the same as in patients in the lower age strata.

The aim of this Working Group was to discuss more in-depth treatment aspects of hypertensive patients aged ≥80 years or older, with special focus on the difficulties and uncertainties posed by very old frail individuals. We focused, in particular, on the following points of the 2013 ESH/ESC guidelines:

- Benefits of treatment.
- Blood pressure (BP) thresholds and targets.
- The choice of treatment.

Benefits of Treatment

The 2013 ESH/ESC guidelines¹ reported the results of the Hypertension in the Very Elderly Double Blind Trial (HYVET). This showed that in hypertensive patients aged ≥80 years, the administration of the thiazide-like diuretic indapamide supplemented, if necessary, by the angiotensin-converting enzyme inhibitor perindopril led to a significant reduction in the risk of major cardiovascular events and all-cause death when compared with placebo.² From this, the guidelines concluded that there is evidence that antihypertensive treatment is beneficial in octogenarians in whom BP is elevated and that, therefore, BP-lowering interventions can be strongly recommended within this age range. However, both the ESH/ESC guidelines¹ and other publications^{5–8} also point out limitations in the demonstration that treatment is beneficial in octogenarians and this need to be addressed. First, the HYVET is to date the only randomized clinical trial that has addressed this important issue, making confirmation by a second trial highly desirable. Second, the age of the HYVET patients was for the most part closer to 80 years (73% in the 80–84 and 22% in the 85–89 range), leaving the effect of treatment in patients close to or >90 years of age largely unexplored. Third, because the trial was prematurely interrupted by the Safety Monitoring Board (because of the evidence of protective effect of BP reduction in the treated group), the follow-up was rather short (median, 1.8 years). Despite the observation that in the HYVET patients the rate of events remained lower in the originally treated group 1 year after the trial termination,⁹ this

From the Department of Geriatrics and FHU CARTAGE, CHU de Nancy and INSERM 1116, Université de Lorraine, Nancy, France (A.B.); Department of Medicine Imperial College, London, United Kingdom (C.J.B.); Department of Geriatrics, Ghent University Hospital, and Ghent University, Ghent, Belgium (M.P.); Geriatric Cardiology and Medicine, University of Florence and Azienda Ospedaliero Universitaria Careggi, Firenze, Italy (A.U.); Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy (E.A.R.); Geriatria ed Accettazione Geriatrica d'Urgenza, IRCCS-INRCA, Ancona, Italy (A.C.); Department of Internal Medicine Hospital Clínico de Valencia, INCLIVA Research Institute, University of Valencia, CIBEROBN ISCIII, Madrid, Spain (J.R.); Department of Internal Medicine and Geriatrics, Jagiellonian University, Cracow, Poland (T.G.); College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (A.D.); University of Helsinki, and Helsinki University Central Hospital, Geriatrics, Helsinki, and Center for Life Course Health Research, University of Oulu, Oulu, Finland (T.S.); and Department of Clinical Medicine, University of Milano-Bicocca, Milan, Italy (G.M.).

A. Benetos, M. Petrovic, A. Ungar, A. Cherubini, T. Grodzicki, and T. Strandberg represent the European Union Geriatric Medicine Society (EUGMS); A. Dominiczak, E. Agabiti Rosei, J. Redon, C.J. Bulpitt, and G. Mancina represent the European Society of Hypertension (ESH).

*A. Benetos and C.J. Bulpitt are chairpersons of the ESH/EUGMS Working group.

This article was sent to Marc L. De Buyzere, Guest Editor, for review by expert referees, editorial decision, and final disposition.

Correspondence to Athanase Benetos, Department of Geriatrics, University Hospital of Nancy, 54511 Vandoeuvre les Nancy, France. E-mail a.benetos@chu-nancy.fr

(*Hypertension*. 2016;67:820–825. DOI: 10.1161/HYPERTENSIONAHA.115.07020.)

© 2016 American Heart Association, Inc.

Hypertension is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.115.07020

requires the duration of benefit to be determined. Finally, the 2013 ESH/ESC guidelines state that the HYVET deliberately recruited patients in good physical and mental conditions and excluded ill and frail individuals, who are common among octogenarians, and also excluded patients with clinically relevant orthostatic hypotension,¹ thereby emphasizing probably the most important limitation of the available information, ie, leaving out of consideration the influence of patients' general health, concomitant medication, and frailty on the decision about antihypertensive treatment implementation.

Post hoc analysis of the HYVET trial did not find a relationship between the benefit of antihypertensive treatment and patients' frailty.¹⁰ This is reassuring for community-dwelling older hypertensives, but it is worth remembering that the HYVET did not include very frail patients and that patients with multiple morbidities and clinically significant cognitive impairment were also excluded. Indeed, both recent observational studies and registries show an important influence of the frailty status on the relationship between BP and outcomes, especially in treated hypertensives. This can be exemplified by studies that show the association between BP and mortality to vary according to the walking speed,¹¹ cognitive function, assessed with the Mini Mental State Examination and disability, measured using the activity of daily living.¹² Indeed, Odden et al¹¹ showed that systolic BP in faster walkers was positively correlated with mortality, whereas no relationship between BP and mortality was observed among slower walkers. Moreover, in patients unable to complete the walk test, BP was negatively associated with the risk of death.⁶ In the Milan Geriatrics study,¹² higher systolic BP values were related to lower mortality among individuals aged ≥ 75 years who had an impaired Mini Mental State Examination (< 25 points) or activity of daily living (< 6 points). Also, the Predictive Value of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population (PARTAGE) study has shown that what applies to middle-aged patients does not necessarily apply to old (≥ 80 years) nursing home residents,^{13–15} ie, the frailest oldest patients. Actually, in this very old frail population, values of BP recorded with clinical standard procedures were similar to those obtained with multiple 3-day morning and evening measurements,¹³ and the negative relationship between the main end point of the study (total mortality and major cardiovascular events) and systolic BP (SBP) was observed with BP measured by a clinician, or self-measured.¹⁴ Interestingly, in this study, the highest mortality rate was observed in patients with $\text{SBP} < 130$ mmHg, who were treated with ≥ 2 antihypertensive drugs, at variance from what was seen in those treated with 1 antihypertensive agent or not receiving any antihypertensive drug at all.¹⁵ Likewise, Mossello et al¹⁶ found a more pronounced cognitive decline in treated old hypertensive patients having mild cognitive impairment or dementia in whom SBP was low (< 128 mmHg). Such an effect was not observed in subjects with low SBP but without antihypertensive treatment.

It is important to remember that both low BP and orthostatic hypotension are associated with syncope, falls, and related injuries and fractures.^{17–19} Therefore, both the benefits (including preserving autonomy) and the risks of antihypertensive therapy should be considered before starting

treatment in the very frail older population. This population is the one at the highest risk of not only hypertension-related cardiovascular events but also hypotension-related events.^{19–21} Hypotension-related events are likely to be more common in real life than in clinical trials in which treatment is delivered by expert physicians and patients are followed up closely. In a recent analysis of a large real-life database, very old individuals showed a significant increase in hospitalizations for hip fracture over the 30 days after initiation of antihypertensive drug treatment.²² This has been previously observed in patients with a mean age of 80 years (between 86 and 100 years; 26%) over the 45 days after antihypertensive treatment initiation.¹⁹

BP Thresholds and Targets

Because in the HYVET, patients were recruited if their entry SBP was ≥ 160 mmHg, this is the SBP value recommended by the 2013 ESH/ESC guidelines at which drug treatment in octogenarians should be started.¹ The threshold for treatment has been set at a lower SBP level (≥ 150 mmHg) in the US 2014 guidelines,⁵ but because octogenarians with entry SBP values < 160 mmHg have never been studied in randomized clinical trials or shown to have beneficial effects of BP-lowering interventions in subgroup data from trials addressing a larger age range, this does not seem to be based on solid evidence. Thus, it remains unsubstantiated whether in this very old patient category grade 1 hypertension, ie, a SBP between 140 and 159 mmHg, might benefit from antihypertensive drugs.

Evidence on the BP goals for treatment in octogenarians is also limited. Both the 2013 ESH/ESC¹ and the US guidelines⁵ recommend adopting the goal set by the HYVET, ie, < 150 mmHg SBP but neither addresses the question of the SBP value below which the treatment may interfere with patients' safety. This is a critical issue because, as mentioned above, (1) observational studies have repeatedly shown that in the very old population, low BP values are associated with an increased morbidity and mortality, (2) somewhat statistically underpowered, randomized Japanese trials have not found clear benefits of SBP reductions < 140 mmHg,^{23,24} and (3) a SBP reduction to < 120 , 130, or even 140 mmHg may be associated with an increased risk of negative outcomes, ie, a J-curve phenomenon that seemed to be especially evident in frail individuals. Although the possibility of reverse causality (ie, greater initial risk as the cause of an excessive BP fall and increased outcomes) cannot be excluded, a pathophysiologically founded hypothesis is that in frail very old subjects, an impairment of the mechanisms preserving perfusion might critically decrease blood flow to vital organs (heart, brain, and kidney).²¹ This is at variance from healthier old individuals in whom no clear negative influence of BP decrease on vital organ perfusion and associated complications has been reported.^{25,26} Therefore, the following multiple questions still remain open. Do frail very old hypertensives get benefits from antihypertensive treatment? Is the benefit similar or different in nonfrail and frail individuals? Should the BP threshold at which to start treatment be higher as recently recommended by guidelines? Which are the BP targets that maximize protection in frail very old patients, without posing a risk to their safety?

The recently published Systolic Blood Pressure Intervention Trial (SPRINT)²⁷ shows that among patients at high cardiovascular risk and already using antihypertensive drugs targeting a SBP of 120 mmHg resulted in lower incidence of major cardiovascular events and death from any cause when compared with patients targeting a SBP of 140 mmHg; this result was also statistically significant in the subgroup (28% of all) of patients aged >75 years. However, in the SPRINT, the number of patients aged ≥80 years has not been reported and may be substantially lower than the 28% (2600) patients aged ≥75 years. Furthermore, interpretation of several aspects of the SPRINT data (lack of beneficial effect on stroke, masking effect of diuretics on signs and symptoms of >3 drug heart failure, BP measuring approach, etc) are still under discussion.^{28,29} Finally, and more importantly, patients with advanced frailty, cognitive decline, loss of autonomy, and living in nursing home were excluded from the trial. Exclusion from trial extended to patients with decompensated heart failure, history of stroke, and diabetes mellitus, ie, conditions commonly associated with hypertension in aged individuals in whom they represent a common cause of death. This is a crucial issue also because in SPRINT, the aggressively treated group showed a substantial increase of hypotension, syncope, electrolyte abnormalities, and renal failure, ie, adverse reactions that are likely to be magnified in very old patients, even more so if frail. Thus, application of the SPRINT results in this population cannot be done unconditionally, also considering that other studies including frail people have not obtained similar results. Although potentially useful to robust old hypertensives, these results may have a limited transferability to frail, very old patients in whom the treatment strategies and the treatment goals should be largely driven by their functional status and comorbidities.

Choice of Treatment

On the basis of trials performed in patients aged ≥60 years, both the 2013 ESH/ESC¹ guidelines and the US guidelines² recommend that the antihypertensive treatment to be implemented in old hypertensive subjects to use the same drug classes that are recommended for younger patients, ie, diuretics, angiotensin receptor antagonists, angiotensin-converting enzyme inhibitors, and calcium channel blockers, with an extension to β-blockers in the ESH/ESC guidelines.¹ On the basis of large meta-analyses, they also consider the above 5 classes similarly protective in old hypertensive individuals although indicating diuretics and calcium channel blockers as the preferred choice in isolated systolic hypertension given the preferential use of these 2 drugs in trials on this condition. Neither the European nor the US guidelines mention any difference in the type of treatment in hypertensive patients aged ≥80 years when compared with patients aged <80 years. In the HYVET, the drugs used were the thiazide-like diuretic indapamide complemented by perindopril in ≈70% of the patients, suggesting a possible preference for a treatment based on a diuretic-angiotensin-converting enzyme inhibitor combination. However, in a prespecified secondary analysis of a Japanese study³⁰ on hypertensive patients aged 75 to 84 years, those receiving an angiotensin receptor antagonist/calcium channel blocker combination showed a reduction in the risk of

stroke when compared with patients receiving an angiotensin receptor antagonist/diuretic combination. Given the evidence that the benefit of treatment largely depends on BP lowering per se,³¹ ie, regardless how it is obtained, the opinion of this Working Group is that in principle the large number of antihypertensive drug classes recommended for younger age strata are suitable for use also in the oldest-old individuals. Except when required for specific clinical conditions (eg, angina pectoris, previous myocardial infarction, and heart failure), the use of β-blockers in these very old hypertensive individuals remains controversial, however.^{32,33}

In the 2013 ESH/ESC guidelines,¹ the suggestion is made to consider initiation of antihypertensive treatment with a 2-drug combination if cardiovascular risk is high, with no distinction between younger and older patients. However, in octogenarians, initial administration of 2 antihypertensive drugs, even when administered at low doses, may put subjects at an unwarranted risk of hypotension, given that homeostatic mechanisms that maintain BP against gravity and other challenges undergo a progressive impairment as age advances.³⁴ Furthermore, increasing the number of the prescribed drugs may increase the probability of adverse drug, drug–drug, and drug–disease reactions and interactions in patients in whom polypharmacy is extremely common because of the frequent concomitance of both cardiovascular and noncardiovascular diseases.^{35,36} Finally, an increased number of prescribed drugs is known to have a negative effect on adherence to treatment, an especially serious problem in very old patients in whom adherence (and errors in taking the prescribed medicines) may be adversely affected by cognitive dysfunction and dementia.³⁷ Combination of 2 antihypertensive drugs should be considered if monotherapy fails to control BP, but only if consideration of the potential protective effect of BP reduction versus the risk of hypotension and other adverse effects makes a benefit likely. As already mentioned in the 2013 ESH/ESC¹ and other guidelines,⁸ antihypertensive treatment in octogenarians should in general not exceed 3 different medications, unless BP remains severely uncontrolled, or patients become 80 under an earlier initiated >3 drug regime, but still well-tolerated, treatment. Under these circumstances, however, patients' follow-up should be intensified because a large body of evidence shows that drug–drug interactions and other iatrogenic problems dramatically increase with an increase in the number of administered drugs and more so in frail patients³⁸

Suggestions of the Working Group for the Management of Hypertension in Octogenarians

Based on the above comments, we propose the following:

Treatment Initiation

The 2013 ESH/ESC guidelines state that in individuals aged ≥80 years with an initial SBP≥160 mmHg, SBP should be reduced by drug treatment provided that patients are in good physical and mental conditions. We believe that this recommendation should be accompanied by (1) a more precise definition of the meaning of the term good physical and mental conditions and (2) an indication of how physical conditions, mental conditions, and the frailty status can be assessed.

A rapid (<10 minutes) assessment of frailty is feasible. The most frequently used is the Fried frailty phenotype³⁹ in which frailty is defined by the presence of at least 3 of the following: weight loss, exhaustion, weakness, decreased gait speed, and diminished physical activity. Other scales used in different countries^{40–42} may also be referred to.

The ESH/ESC guidelines also state, that continuation of a well-tolerated antihypertensive treatment should be considered when a treated individual becomes octogenarian. This is a reasonable recommendation, but we suggest that in this case, physicians are advised to monitor the frailty status to detect when a change in treatment strategy may be needed.

Treatment Goals

The 2013 ESH/ESC guidelines recommend treatment to lower SBP to <150 mmHg in octogenarians in good physical and mental conditions. We believe that this might be usefully complemented by mentioning that, while keeping <150 mmHg SBP as the evidence-based target, for safety reasons antihypertensive drugs should be reduced or even stopped if SBP is lowered to <130 mmHg, thus keeping the 150 to 130 mmHg on-treatment SBP values as a safety range. Self-assessment of BP at home and if necessary 24-hour ambulatory BP measurements can contribute to identify treated patients with too low BP levels. Some consideration should also be given to the assessment of subclinical organ damage, in particular, left ventricular systolic and diastolic dysfunction as well as arterial stiffness. However, the question is raised about the prognostic significance of these parameters in older hypertensives, and whether their improvement would actually translate into an improvement in mortality in the elderly.⁴³ It should be emphasized that nearly all guidelines on BP targets refer to office BP values because no outcome trial has addressed the optimal out-of-office BP target in older or younger hypertensive patient strata. To date, what has been established is that (1) office BP is higher than 24-hour mean or home BP⁴⁴ and (2) this discrepancy decreases progressively as office BP decreases. This suggests that these values do not differ substantially in individuals with office BP controlled,⁴⁵ a possibility, however, that needs to be tested by randomized trials.

Choice of Antihypertensive Drugs

The 2013 ESH/ESC guidelines¹ recommend all 5 major antihypertensive drug classes (with a preference for diuretics and calcium channel blockers in isolated systolic hypertension) for use in old hypertensive subjects, with no distinction between those aged above or below 80 years. We suggest that a distinction should be made and that, based on the HYVET, in octogenarians, angiotensin-converting enzyme inhibitors and thiazide-like diuretics should be positioned at the same level as calcium channel blockers. The working group thinks that despite the age-related high cardiovascular risk, initial high dose or combination of treatment should not be encouraged, and that combination of treatment should only be considered after failure of initial low-dose therapy.

Frail Very Old Patients (People Living in Nursing Homes or Needing Assistance on a Daily Basis for Their Basic Activities)

The 2013 ESH/ESC guidelines state that “in frail older patients, it is recommended to leave decisions on antihypertensive

therapy to the treating physician, and base them on monitoring of the clinical effects of treatment.” We suggest that in these patients, therapeutic decisions should be preceded by (1) accurate information on their functional capacity, cognitive status. Although notoriously difficult, an estimate of patient’s prognosis should also be attempted; (2) attention to multiple drug administration so common in this age stratum; (3) stratification of the frailty status by one of the available rapid methods; and (4) identification and correction of factors that predispose to an excessive BP reduction, orthostatic hypotension, and other hypotensive episodes, such as concomitant treatments, malnutrition, and dehydration. The decision of the practicing physician to start treatment in a frail very old patient should be especially cautious (low drug doses and monotherapy) and patient status should be checked on a frequent basis.

It is obvious that the recommendations of our group pertain mainly to very old people (ie, ≥80 years) with frailty. However, we believe that an individual in his late sixties or early seventies who expresses the condition of frailty—and in whom at that moment a difference between the calendar and the biological age becomes apparent—should be approached in a similar way. Because prevalence of frailty dramatically increases with increasing age,⁴⁶ the latter situation, however, would take place in few cases. For this reason, a systematic screening for frailty, which we propose for very old people, might take place in their younger counterparts only when a clinical and functional problems become imminent.

Finally, we would like to point out that research based on not only registries, administrative databases but also interventional controlled trials should be favored to assess the benefits/risks ratio of multidrug antihypertensive treatment in the growing population of very old frail patients.

Disclosures

The authors of this article declared the following potential conflicts of interest related to their activities during the last 24 months: A. Benetos received speaker’s fees from Novartis and Fukuda. C. Bulpitt received grants from Servier. E. Agabiti Rosei has received honoraria for lectures or grants for research from the following companies: Menarini International, Recordati International, Servier, Novartis, Sanofi Aventis, and DOC generici. J. Redon received honoraria for participating in the Advisory Board of Menarini, Daiichi-Sankyo, GSK and for giving lectures for Menarini, Daiichi-Sankyo, Boehringer-Ingelheim. T. Grodzicki has received speaker’s or consultation fees from Abbott, Adamed, Sanofi, and Servier. T. Strandberg reports personal fees from Amgen, AstraZeneca, Pfizer, Orion, Bayer, Boehringer-Ingelheim, Nutricia, and Abbott. G. Mancina received speaker’s or consultation fees from: Actavis, Bayer, Boehringer-Ingelheim, Covidien, CVRx, Daiichi Sankyo, Ferrer, Lilly, Medtronic Vascular Inc, Menarini Int. Merck Serono, MSD, Novartis, Recordati, Sanofi, Servier, and Takeda. The other authors report no conflicts.

References

1. Authors/Task Force Members; Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013; 34:2159–2219.
2. National Institute on Aging, National Institutes of Health. Global Health and Aging. NIH Publication no. 11–7737. Washington, DC: World Health Organisation; 2011.
3. Health at a Glance 2009–OECD Indicators. <http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCIQFjAA&url=http%3A%2F%2Fwww.oecd.org%2Fhealth%2Fhealth-systems%2F44117530>

- pdf&ei=DvK7VN7SJMxkasigrAI&usq=AFQjCNHKC9qNe87Gdi-Bli_VTS0dfWpigg&bvm=bv.83829542,d.2s&cad=rja). Accessed October 2015.
4. Berrut G, Andrieu S, Araujo De Carvalho I, et al. Promoting access to innovation for frail old persons. IAGG (International Association of Gerontology and Geriatrics), WHO (World Health Organization) and SFGG (Societe Francaise de Geriatrie et de Gerontologie) Workshop—Athens January 20–21, 2012. *J Nutr Health Aging*. 2013;17:688–693.
 5. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens*. 2014;32:3–15. doi: 10.1097/HJH.0000000000000065.
 6. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *J Am Soc Hypertens*. 2011;5:259–352. doi: 10.1016/j.jash.2011.06.001.
 7. National Institute for Health and Care Excellence. <http://www.nice.org.uk/guidance/cg127/resources/guidance-hypertension-pdf>. Accessed October 2015.
 8. Blacher J, Halimi JM, Hanon O, Mourad JJ, Pathak A, Schnebert B, Girerd X; French Society of Hypertension. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. *Fundam Clin Pharmacol*. 2014;28:1–9. doi: 10.1111/fcp.12044.
 9. Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C; HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. *BMJ*. 2012;344:d7541.
 10. Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, Bulpitt C, Peters R. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. *BMC Med*. 2015;13:78. doi: 10.1186/s12916-015-0328-1.
 11. Odden MC, Covinsky KE, Neuhaus JM, Mayeda ER, Peralta CA, Haan MN. The association of blood pressure and mortality differs by self-reported walking speed in older Latinos. *J Gerontol A Biol Sci Med Sci*. 2012;67:977–983. doi: 10.1093/gerona/glr245.
 12. Ogliari G, Westendorp RG, Muller M, Mari D, Torresani E, Felicetta I, Lucchi T, Rossi PD, Sabayan B, de Craen AJ. Blood pressure and 10-year mortality risk in the Milan Geriatrics 75+ Cohort Study: role of functional and cognitive status. *Age Ageing*. 2015;44:932–937. doi: 10.1093/ageing/afv141.
 13. Benetos A, Buatois S, Salvi P, et al. Blood pressure and pulse wave velocity values in the institutionalized elderly aged 80 and over: baseline of the PARTAGE study. *J Hypertens*. 2010;28:41–50. doi: 10.1097/HJH.0b013e328332b879.
 14. Benetos A, Gautier S, Labat C, et al. Mortality and cardiovascular events are best predicted by low central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly nursing home subjects: the PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population) study. *J Am Coll Cardiol*. 2012;60:1503–1511. doi: 10.1016/j.jacc.2012.04.055.
 15. Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, Salvi P, Zamboni M, Manckoundia P, Hanon O, Gautier S. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: The PARTAGE Study. *JAMA Intern Med*. 2015;175:989–995. doi: 10.1001/jamainternmed.2014.8012.
 16. Mossello E, Pieracciolli M, Nesti N, Bulgaresi M, Lorenzi C, Caleri V, Tonon E, Cavallini MC, Baroncini C, Di Bari M, Baldasseroni S, Cantini C, Biagini CA, Marchionni N, Ungar A. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. *JAMA Intern Med*. 2015;175:578–585. doi: 10.1001/jamainternmed.2014.8164.
 17. Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Møller O. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmö Preventive Project). *Eur Heart J*. 2010;31:85–91. doi: 10.1093/eurheartj/ehp329.
 18. Angelousi A, Girerd N, Benetos A, Frimat L, Gautier S, Weryha G, Boivin JM. Association between orthostatic hypotension and cardiovascular risk, cerebrovascular risk, cognitive decline and falls as well as overall mortality: a systematic review and meta-analysis. *J Hypertens*. 2014;32:1562–1571; discussion 1571. doi: 10.1097/HJH.0000000000000235.
 19. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. *Arch Intern Med*. 2012;172:1739–1744. doi: 10.1001/2013.jamainternmed.469.
 20. van der Wardt V, Logan P, Conroy S, Harwood R, Gladman J. Antihypertensive treatment in people with dementia. *J Am Med Dir Assoc*. 2014;15:620–629. doi: 10.1016/j.jamda.2014.03.005.
 21. Muller M, Smulders YM, de Leeuw PW, Stehouwer CD. Treatment of hypertension in the oldest old: a critical role for frailty? *Hypertension*. 2014;63:433–441. doi: 10.1161/HYPERTENSIONAHA.113.00911.
 22. Corrao G, Mazzola P, Monzio Compagnoni M, Rea F, Merlino L, Annoni G, Mancia G. Antihypertensive Medications, Loop Diuretics, and Risk of Hip Fracture in the Elderly: A Population-Based Cohort Study of 81,617 Italian Patients Newly Treated Between 2005 and 2009. *Drugs Aging*. 2015;32:927–936. doi: 10.1007/s40266-015-0306-5.
 23. Rakugi H, Ogihara T, Goto Y, Ishii M; JATOS Study Group. Comparison of strict- and mild-blood pressure control in elderly hypertensive patients: a per-protocol analysis of JATOS. *Hypertens Res*. 2010;33:1124–1128. doi: 10.1038/hr.2010.144.
 24. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. *Hypertension*. 2010;56:196–202. doi: 10.1161/HYPERTENSIONAHA.109.146035.
 25. Foster-Dingley JC, Moonen JE, de Craen AJ, de Ruijter W, van der Mast RC, van der Grond J. Blood pressure is not associated with cerebral blood flow in older persons. *Hypertension*. 2015;66:954–960. doi: 10.1161/HYPERTENSIONAHA.115.05799.
 26. Lipsitz LA, Habtemariam D, Gagnon M, Iloputaife I, Sorond F, Tchalla AE, Dantoine TF, Trivison TG. Reexamining the effect of antihypertensive medications on falls in old age. *Hypertension*. 2015;66:183–189. doi: 10.1161/HYPERTENSIONAHA.115.05513.
 27. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103–2116.
 28. Mancia G. The SPRINT trial: cons. <http://www.acc.org/latest-in-cardiology/articles/2015/12/01/10/04/the-sprint-trial-cons>. Accessed January 26, 2016.
 29. Touyz RM, Dominiczak AF. Successes of SPRINT, but Still Some Hurdles to Cross. *Hypertension*. 2016;67:268–269. doi: 10.1161/HYPERTENSIONAHA.115.06725.
 30. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Teramukai S, Higaki J, Ito S, Shimada K; COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. *Hypertens Res*. 2015;38:89–96. doi: 10.1038/hr.2014.144.
 31. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med*. 2005;165:1410–1419.
 32. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. *CMAJ*. 2006;174:1737–1742. doi: 10.1503/cmaj.060110.
 33. Wiyongse CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007;1:CD002003.
 34. Ebert TJ, Morgan BJ, Barney JA, Denahan T, Smith JJ. Effects of aging on baroreflex regulation of sympathetic activity in humans. *Am J Physiol*. 1992;263(3 pt 2):H798–H803.
 35. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. *Expert Opin Drug Saf*. 2014;13:57–65. doi: 10.1517/14740338.2013.827660.
 36. Benetos A, Rossignol P, Cherubini A, Joly L, Grodzicki T, Rajkumar C, Strandberg TE, Petrovic M. Polypharmacy in the aging patient: management of hypertension in octogenarians. *JAMA*. 2015;314:170–180. doi: 10.1001/jama.2015.7517.

37. Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. *J Hypertens*. 2014;32:1708–1715; discussion 1716. doi: 10.1097/HJH.0000000000000222.
38. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. *Am J Emerg Med*. 1996;14:447–450. doi: 10.1016/S0735-6757(96)90147-3.
39. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56:M146–M156.
40. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. *JAMA*. 2011;305:50–58. doi: 10.1001/jama.2010.1923.
41. Romero-Ortuno R, Soraghan C. A Frailty Instrument for primary care for those aged 75 years or more: findings from the Survey of Health, Ageing and Retirement in Europe, a longitudinal population-based cohort study (SHARE-FI75+). *BMJ Open*. 2014;4:e006645. doi: 10.1136/bmjopen-2014-006645.
42. Abellan van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, Vellas B. The I.A.N.A Task Force on frailty assessment of older people in clinical practice. *J Nutr Health Aging*. 2008;12:29–37.
43. Zhang Y, Agnoletti D, Xu Y, Wang JG, Blacher J, Safar ME. Carotid-femoral pulse wave velocity in the elderly. *J Hypertens*. 2014;32:1572–6; discussion 1576. doi: 10.1097/HJH.0000000000000187.
44. O'Brien E, Parati G, Stergiou G, et al.; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. *J Hypertens*. 2013;31:1731–1768. doi: 10.1097/HJH.0b013e328363e964.
45. Mancia G, Parati G, Bilo G, et al. Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). *Hypertension*. 2012;60:1400–1406. doi: 10.1161/HYPERTENSIONAHA.112.199562.
46. Gale CR, Cooper C, Sayer AA. Prevalence of frailty and disability: findings from the English Longitudinal Study of Ageing. *Age Ageing*. 2015;44:162–165. doi: 10.1093/ageing/afu148.

An Expert Opinion From the European Society of Hypertension–European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects

Athanase Benetos, Christopher J. Bulpitt, Mirko Petrovic, Andrea Ungar, Enrico Agabiti Rosei, Antonio Cherubini, Josep Redon, Tomasz Grodzicki, Anna Dominiczak, Timo Strandberg and Giuseppe Mancia

Hypertension. 2016;67:820-825; originally published online March 14, 2016;
doi: 10.1161/HYPERTENSIONAHA.115.07020

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://hyper.ahajournals.org/content/67/5/820>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Hypertension* is online at:
<http://hyper.ahajournals.org/subscriptions/>